Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 1
Forward-Looking Information During this meeting, we will make statements about the Company s future plans and prospects that constitute forwardlooking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. 2
Evolution of BioPharma Strategy Innovative Pharmaceuticals Specialty Care BioPharma 2007 2013 3
BMS R&D Focus Disease Area Focus Drug Platforms Immuno-Oncology Oncology Immunoscience Cardiovascular Small Molecules Biologics Virology Fibrotic Diseases Exploratory Areas Metabolics * Antibody Drug Conjugates Millamolecules * Focus on progressing early-development assets and transitioning late-stage assets to AstraZeneca 4
BMY Development Portfolio by Disease Area Data as of Feb 1, 2014 Phase I Phase II Phase Marketed Product III^ Development Anti-LAG3 Anti-CD28 Eldelumab (Anti-IP10) Nivolumab NULOJIX Denenicokin (IL-21) Anti-IL31 Clazakizumab Elotuzumab SPRYCEL ELIQUIS Lirilumab (Anti-KIR) Factor XIa Inhibitor HIV Attachment Inhibitor NS5B Non Nuc ERBITUX BARACLUDE Urelumab (Anti-CD137) IKur Inhibitor NRT Inhibitor Daclatasvir ORENCIA REYATAZ JAK2 Inhibitor PAR4 Antagonist HIV Program ++ Asunaprevir Notch Inhibitors Anti-PD-L1 LPA1 Antagonist Peginterferon lambda-1a Anti-CXCR4 CCR2 / 5 (2) Antagonist CCR2 / 5 (1) Antagonist Anti-CD40L PEG-FGF21 ^In Phase III development or currently under regulatory review ++ Mechanism of Action is not disclosed IO ONC IMM CV Approved in at least one major market (US, EU, JP, CN) VIR FD EA MET 5
2013 Pipeline Highlights Cardiovascular Submission of Eliquis VTE prevention and treatment Hepatitis C Submission of daclatasvir and asunaprevir regimen in Japan (DUAL) Submission of daclatasvir in the EU Initiation of Phase III for the daclatasvir / asunaprevir / NS5B fixed dose combination tablet (Triple) Immuno-Oncology Nivolumab monotherapy and combination data at ASCO Nivolumab lung data at WCLC Progression and initiation of several potentially registrational trials Yervoy pooled long-term survival data 6
Immuno-Oncology: Transformational Potential Yervoy: first agent to demonstrate long-term survival in some patients with metastatic melanoma Nivolumab: comprehensive development program Multiple tumor types, histologies, and lines of therapy Exploring the role of biomarkers Monotherapy and combination Broad early stage portfolio 7
Immuno-Oncology Development Portfolio Phase I Urelumab (Anti-CD137) Cancer HCC Phase II Elotuzumab* 2nd line MM Velcade Combo NHL (FL)^ NHL (DLBCL)^ Cancer (solid tumor) Hematologic Mal. Anti-LAG3 + Cancer Lirilumab + Cancer (solid tumor) Gastric Ovarian Denenicokin + Adolescent melanoma Lirilumab + Glioblastoma^ Cancer (solid tumor) + Cancer (solid tumor) Elotuzumab* Elotuzumab* 2nd line Sq NSCLC 2nd line NSq NSCLC 3rd line Sq NSCLC + SPRYCEL CML^ Unresectable or Metastatic Melanoma Adjuvant Melanoma 1st line Sq NSCLC Small Cell Lung Prostate (posthormonal therapy) 1st line Melanoma 1st line NSCLC (PD-L1 +) Cancer (RCC) 1st line Melanoma 2nd/3rd line RCC + + Metastatic Melanoma Dose Optimization 2nd/3rd line Melanoma Cancer (NSCLC) + Relapsed/Refractory MM Revlimid Combo + Cancer (solid tumor) Approved Indications Registrational 1st line MM Revlimid Combo Data as of Feb 1, 2014 ^ * Development Partnership Nivolumab: Ono Pharmaceuticals; Elotuzumab: AbbVie; Lirilumab: Innate Pharma ^Published on ClinicalTrials.gov, not yet recruiting Abbreviations CML: Chronic Myelogenous Leukemia DLBCL: Diffuse Large B-cell Lymphoma FL: Follicular Lymphoma HCC: Hepatocellular Carcinoma Mal: Malignancy, Met: Metastatic MM: Multiple Myeloma NHL: Non-Hodgkin Lymphoma NSq: Non-Squamous, Sq: Squamous NSCLC: Non Small Cell Lung Cancer RCC: Renal Cell Carcinoma 8
Key Data Flow & Events: 2014 Potential approval in VTE treatment in the US and EU Potential approval in VTE prevention in the US Hepatitis C Portfolio Potential approval of daclatasvir and asunaprevir in Japan (DUAL) Potential approval of daclatasvir in the EU Potential submission of daclatasvir and asunaprevir in the US Adjuvant melanoma data Additional combination data with nivolumab Nivolumab (Anti-PD1) Data from Phase II 3 rd line squamous NSCLC Phase I combinations in NSCLC and renal Additional follow-up, including long term survival, from Phase I monotherapy study in lung, renal and melanoma Additional follow-up, including long tem survival, from Phase I combination study with ipilimumab in melanoma Initiation of additional trials and in additional indications Note: Dependent on data availability, acceptance of medical meeting submissions or health authority actions 9
Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 10